Costco Increases Annual Dividend to $5.20, Continuing 20-Year Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Yahoo Finance
- Consistent Dividend Growth: Costco (COST) has increased its quarterly dividend for over 20 years, with the current annual payout at $5.20 per share, reflecting a strong commitment to shareholder value despite a yield below 1% due to significant stock price appreciation driven by robust business performance.
- Special Dividend Returns: The company periodically issues large special dividends, the latest being $15 per share in December 2023, which not only enhances shareholder returns but also demonstrates flexibility and sound cash flow management in its financial strategy.
- Strong Financial Performance: For the fiscal year ending August 31, 2025, Costco reported annual revenue of $275.2 billion, an 8.2% increase year-over-year, with Q1 revenue reaching $67.31 billion, also up 8.3%, indicating strong market performance even amid economic uncertainties.
- Membership Model Advantage: Costco's high-margin membership model generated over $1.3 billion in revenue in Q1 fiscal 2026, ensuring customer loyalty with a renewal rate of 92%, which allows the company to operate on thin margins while providing significant savings to its members.
ABBV
$229.98+Infinity%1D
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 248.67 USD with a low forecast of 204.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
24 Analyst Rating
15 Buy
9 Hold
0 Sell
Moderate Buy
Current: 229.890
Low
204.00
Averages
248.67
High
289.00
Current: 229.890
Low
204.00
Averages
248.67
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
